131 related articles for article (PubMed ID: 1991683)
1. Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems.
Kallman RF; Rapacchietta D; Zaghloul MS
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):227-32. PubMed ID: 1991683
[TBL] [Abstract][Full Text] [Related]
2. The effect of treatment in fractionated schedules with the combination of X-irradiation and six cytotoxic drugs on the RIF-1 tumor and normal mouse skin.
Lelieveld P; Scoles MA; Brown JM; Kallman RF
Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):111-21. PubMed ID: 4038500
[TBL] [Abstract][Full Text] [Related]
3. Effects of fractionated schedules of irradiation combined with cis-diamminedichloroplatinum II on the SCCVII/St tumor and normal tissues of the C3H/KM mouse.
Tanabe M; Godat D; Kallman RF
Int J Radiat Oncol Biol Phys; 1987 Oct; 13(10):1523-32. PubMed ID: 3624028
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent therapeutic gain from the combination of fractionated irradiation and cis-diamminedichloroplatinum (II) in C3H/Km mouse model systems.
Kanazawa H; Rapacchietta D; Kallman RF
Cancer Res; 1988 Jun; 48(11):3158-64. PubMed ID: 2966671
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation.
Bartelink H; Kallman RF; Rapacchietta D; Hart GA
Radiother Oncol; 1986 May; 6(1):61-74. PubMed ID: 3715061
[TBL] [Abstract][Full Text] [Related]
6. The importance of schedule and drug dose intensity in combinations of modalities.
Kallman RF
Int J Radiat Oncol Biol Phys; 1994 Feb; 28(3):761-71. PubMed ID: 8113123
[TBL] [Abstract][Full Text] [Related]
7. Temporal interactions in the Lewis lung tumour between cytotoxic drugs and acute or fractionated radiotherapy.
Stephens TC; Adams K; Peacock JH; Steel GG
Radiother Oncol; 1986 Feb; 5(2):137-46. PubMed ID: 3704188
[TBL] [Abstract][Full Text] [Related]
8. Effects of matrix-associated chemotherapy in combination with irradiation in vivo.
Howes AE; Herman TS; Montoya VP; Luck EE; Brown DM
NCI Monogr; 1988; (6):141-3. PubMed ID: 3352756
[TBL] [Abstract][Full Text] [Related]
9. Early and late changes in the normal mouse bladder reservoir function due to irradiation and cis-DDP.
Lundbeck F; Overgaard J
Br J Cancer; 1992 Jul; 66(1):99-105. PubMed ID: 1637684
[TBL] [Abstract][Full Text] [Related]
10. Interactions of radiation and cancer chemotherapeutic drugs in a C3H mouse mammary carcinoma.
von der Maase H; Overgaard J
Acta Radiol Oncol; 1985; 24(2):181-7. PubMed ID: 2988283
[TBL] [Abstract][Full Text] [Related]
11. Early and late damage in the mouse bladder after radiation combined with cyclophosphamide or cisplatinum, evaluated by two different functional assays.
Lundbeck F; Oussoren Y; Stewart FA
Acta Oncol; 1993; 32(6):679-87. PubMed ID: 8260188
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 modification of the effects of cyclophosphamide and fractionated irradiation.
Dorie MJ; Kallman RF; Cebulska-Wasilewska A
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):311-4. PubMed ID: 1991694
[TBL] [Abstract][Full Text] [Related]
13. The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platin.
Palmeri S; Trave F; Russello O; Rustum YM
Sel Cancer Ther; 1989; 5(4):169-77. PubMed ID: 2623382
[TBL] [Abstract][Full Text] [Related]
14. Protection by WR-2721 against radiation plus cis-diamminedichloroplatinum II caused injury to colonic epithelium in mice.
Ito H; Komaki R; Milas L
Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):899-903. PubMed ID: 8138443
[TBL] [Abstract][Full Text] [Related]
15. The influence of cisplatin on the response of mouse kidneys to multifraction irradiation.
Stewart FA; Oussoren Y; Bartelink H
Radiother Oncol; 1989 May; 15(1):93-102. PubMed ID: 2748946
[TBL] [Abstract][Full Text] [Related]
16. Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage: a prospective clinical study.
Mah K; Keane TJ; Van Dyk J; Braban LE; Poon PY; Hao Y
Int J Radiat Oncol Biol Phys; 1994 Feb; 28(3):563-74. PubMed ID: 7509329
[TBL] [Abstract][Full Text] [Related]
17. Chemopotentiation in vivo: no loss of sensitization with fractionation.
Hill SA; Siemann DW
Br J Cancer; 1984 Oct; 50(4):509-17. PubMed ID: 6487517
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
19. Response of murine tumors to matrix-associated cisplatin intratumoral implants.
Yu NY; Conley FK; Luck EE; Brown DM
NCI Monogr; 1988; (6):137-40. PubMed ID: 3352755
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy for advanced bladder cancer: clinical evaluation of chemotherapy for locally advanced or metastatic bladder cancer and adjuvant chemotherapy for deeply invasive bladder cancer following radical cystectomy].
Uekado Y; Ogawa T; Yoshida T; Yamamoto S; Hirano A; Watanabe T; Shinka T; Ohkawa T
Hinyokika Kiyo; 1985 Aug; 31(8):1365-70. PubMed ID: 3841260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
